Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$1.76 USD
-0.04 (-2.22%)
Updated Jul 29, 2024 03:58 PM ET
After-Market: $1.79 +0.03 (1.70%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
LUMO 1.76 -0.04(-2.22%)
Will LUMO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LUMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LUMO
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
LUMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
Other News for LUMO
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
Lumos Pharma Announces Governance Decisions and Trial Updates
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
Lumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ...